Literature DB >> 20624776

Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy.

Ana Márcia M Mattos1, Caroline de S Almeida, Kees L M C Franken, Caio César de S Alves, Clarice Abramo, Maria Aparecida de Souza, Marcos L'Hotellier, Márcio J M Alves, Ana Paula Ferreira, Sérgio C Oliveira, Tom H M Ottenhoff, Henrique C Teixeira.   

Abstract

Detection of specific antibodies may represent an additional tool in diagnosis of tuberculosis (TB). Herein, levels of serum IgG antibodies against early secreted antigenic target (ESAT-6), culture filtrate antigen-10 (CFP-10) and 16 kDa Mycobacterium tuberculosis antigens were measured in 33 active pulmonary TB patients (0M-TB), in 47 patients after 1-3 months of treatment (3M-TB) and in 22 patients who had completed 6 months of chemotherapy (6M-TB). The control group consisted of 38 BCG-vaccinated healthy controls (HC). In addition, IFN-gamma, tumor necrosis factor (TNF)-alpha, IL-6, IL-2, IL-4 and IL-10 production in PBMC cultures from 20 patients were measured following stimulation with the M. tuberculosis-specific fusion protein ESAT-6/CFP-10. Elevated levels of IgG against ESAT-6, CFP-10 and 16 kDa antigens were detected in 0M-TB and 3M-TB patients in comparison to the HC and 6M-TB groups. Receiver operating characteristic analysis indicated sensitivity of 85, 94 and 61% and specificity of 89, 87 and 89% for serum IgG against ESAT-6, CFP-10 and 16 kDa, respectively. A predominant IgG1 response to ESAT-6 and CFP-10 was observed in 0M-TB patients, together with ESAT-6/CFP-10-specific IFN-gamma, TNF-alpha and IL-6 that were produced at lower levels in the 6M-TB group. These data indicate that a T(h)1 phenotype against early phase Mtb antigens appears to be dominant in the peripheral blood of patients with active pulmonary TB that is reduced after chemotherapy. Taken together, ESAT-6/CFP-10 cytokine tests together with detecting IgG antibodies specific to ESAT-6 and CFP-10 may be the useful TB disease biomarkers in monitoring treatment success.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624776     DOI: 10.1093/intimm/dxq429

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  34 in total

1.  Multifunctional T Cell Response to DosR and Rpf Antigens Is Associated with Protection in Long-Term Mycobacterium tuberculosis-Infected Individuals in Colombia.

Authors:  Leonar Arroyo; Mauricio Rojas; Kees L M C Franken; Tom H M Ottenhoff; Luis F Barrera
Journal:  Clin Vaccine Immunol       Date:  2016-10-04

2.  Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic.

Authors:  Gul Ahmad; Weidong Zhang; Workineh Torben; Afzal Ahrorov; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Pauline N M Mwinzi; Lisa Ganley-Leal; Ronald C Kennedy; Afzal A Siddiqui
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

3.  Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons.

Authors:  Souvik Karmakar; Weidong Zhang; Gul Ahmad; Workineh Torben; Mayeen U Alam; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  Vaccine       Date:  2014-01-04       Impact factor: 3.641

4.  Characterization of Th1- and Th2-type immune response in human multidrug-resistant tuberculosis.

Authors:  Q Tan; W P Xie; R Min; G Q Dai; C-C Xu; H Q Pan; C D Miao; Z Yang; W G Xu; H Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-25       Impact factor: 3.267

5.  Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in patients with active pulmonary tuberculosis.

Authors:  Desta Kassa; Leonie Ran; Wudneh Geberemeskel; Mekashaw Tebeje; Amelewerk Alemu; Alemayehu Selase; Belete Tegbaru; Kees L M C Franken; Annemieke H Friggen; Krista E van Meijgaarden; Tom H M Ottenhoff; Dawit Wolday; Tsehaynesh Messele; Debbie van Baarle
Journal:  Clin Vaccine Immunol       Date:  2012-09-26

6.  Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production.

Authors:  Yun Hee Jeong; Yun-Gyoung Hur; Hyejon Lee; Sunghyun Kim; Jang-Eun Cho; Jun Chang; Sung Jae Shin; Hyeyoung Lee; Young Ae Kang; Sang-Nae Cho; Sang-Jun Ha
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

Review 7.  Immunological biomarkers of tuberculosis.

Authors:  Gerhard Walzl; Katharina Ronacher; Willem Hanekom; Thomas J Scriba; Alimuddin Zumla
Journal:  Nat Rev Immunol       Date:  2011-04-08       Impact factor: 53.106

8.  Increased cytokines response in patients with tuberculosis complicated with chronic obstructive pulmonary disease.

Authors:  Shenjie Tang; Haiyan Cui; Lan Yao; Xiaohui Hao; Yun Shen; Lin Fan; Hua Sun; Zhanjun Zhang; Jian An Huang
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa.

Authors:  Aida Sivro; Lyle R McKinnon; Nonhlanhla Yende-Zuma; Santhana Gengiah; Natasha Samsunder; Salim S Abdool Karim; Kogieleum Naidoo
Journal:  Clin Infect Dis       Date:  2017-09-01       Impact factor: 9.079

10.  Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?

Authors:  Diego L Costa; Eduardo P Amaral; Sivaranjani Namasivayam; Lara R Mittereder; Bruno B Andrade; Alan Sher
Journal:  Front Cell Infect Microbiol       Date:  2021-06-21       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.